CPIX vs. LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, JAZZ, and CORT
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs. Its Competitors
Eli Lilly and Company (NYSE:LLY) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.
Eli Lilly and Company has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Eli Lilly and Company has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.
Eli Lilly and Company presently has a consensus target price of $950.17, indicating a potential upside of 29.76%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals.
82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 44.9% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Eli Lilly and Company has a net margin of 25.91% compared to Cumberland Pharmaceuticals' net margin of -6.97%. Eli Lilly and Company's return on equity of 92.72% beat Cumberland Pharmaceuticals' return on equity.
In the previous week, Eli Lilly and Company had 182 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 184 mentions for Eli Lilly and Company and 2 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.66 beat Cumberland Pharmaceuticals' score of 0.63 indicating that Eli Lilly and Company is being referred to more favorably in the media.
Summary
Eli Lilly and Company beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access